Novartis Résultat pour le premier trimestre 2003

April 15, 2003 01:15 ET | Source: Novartis Pharma AG Novartis Pharma AG

For release content, please refer to the attachment.

Attachments

Media Release...

Recommended Reading

April 27, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi1Rhapsido recommended in 2026...
Read More
April 24, 2026 06:30 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma...
Read More